
Vali oma silt
näidatakse otse viaalilReta + Tesamorelin Blend
GLP-1
- Saadetakse Saksamaalt
Tellimus
- DHL koos jälgimisega
- Diskreetne pakend
Lühidalt
Reta + Tesamorelin Blend arvudes
Põhinäitajad meie leksikonist.
Täielik leksikoni artikkel- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Arvustused
Mida kliendid ütlevad
Ainult päris tellimused, milles oli Reta + Tesamorelin Blend.
Kõik arvustusedReta + Tesamorelin Blend jaoks pole veel laborianalüüsi. Hääleta selle pooltLase ise testida, meie maksame pooleKõik laborianalüüsid
Teadmised
Kõik teemal Reta + Tesamorelin Blend
Üksikasjalik teave tuleb peagi.
Annustamine
Annustamisteabe laadimine …
Telli kohe kaasa
Mida sul sellega vaja on
Bakteriostaatiline vesi lisatakse ostukorvi automaatselt. Süstlad ja lapid ühe klõpsuga.
Insuliinisüstlad
10 tk · 5.50 €
Alkoholilapid
50 tk · 10 €
Kui palju vett?
Ühikud süstlal sinu viaali suuruse jaoks.
Ava kalkulaator →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Seotud
Seotud tooted
Tirzepatide
Peptiidid · GLP-1 ja rasvapõletus GLP-1 ja rasvapõletus
10 suurust
Laboris testitud
= alates 10 €/viaal
Retatrutide
Peptiidid · GLP-1 ja rasvapõletus GLP-1 ja rasvapõletus
11 suurust
Laboris testitud
= alates 16 €/viaal
Semaglutide
Peptiidid · GLP-1 ja rasvapõletus GLP-1 ja rasvapõletus
6 suurust
Laboris testitud
= alates 10 €/viaal
Mazdutide
Peptiidid · GLP-1 ja rasvapõletus GLP-1 ja rasvapõletus
2 suurust
= alates 32 €/viaal
Reta + Tesamorelin Blend